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Abstract
Background: Cancer survivorship is of increasing importance in post-treatment care. Sexual health (SH) and
femininity can be crucial issues for women surviving cancer. We aimed to determine a more complete
understanding of the contribution that a breast cancer (BC) diagnosis and its treatment exert on patients’
follow-up SH. For this purpose, self-reported levels and predictors of SH in breast cancer survivors (BCS) were
compared with those of women with no previous or current BC (WNBC).
Methods: BCS and WNBC underwent a comprehensive, cross-sectional patient-reported outcome (PRO)
assessment. Validated PRO instruments were used to measure SH, body image, anxiety and depression and
menopausal symptoms. Assessments were performed within the routine clinical setting.
Instruments used were the Sexual Interest and Desire Inventory - Female, Sexual Activity Questionnaire, Body
Image Scale, Hospital Anxiety and Depression Scale and the Menopause-Specific Quality of Life Questionnaire.
Results: One hundred five BCS (average time since diagnosis of 3 years) and 97 WNBC with a mean age of 49 years
completed the assessment. SH was significantly worse in BCS compared to WNBC (p = 0.005; BCS SIDI-F mean = 24.9
vs. WNBC mean = 29.8). 68.8% of BCS and 58.8% of WNBC met criteria of a hypo-active sexual desire disorder. Higher
depressive symptoms, higher age and lower partnership satisfaction were predictive for poorer SH in BCS.
Conclusion: SH problems are apparent in BCS and differ significantly from those seen in the general population.
Consequently, BC survivorship care should include interventions to ameliorate sexual dysfunction and provide help
with depressive symptoms and partnership problems, which are associated with poor BCS SH.
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Background
A decrease in breast cancer (BC) mortality and improved
screening and treatment options has lead to a steadily in-
creasing group of breast cancer survivors (BCS), which in
turn create new demands in survivorship health care [1–5].
Quality of life (QoL) issues are of high relevance in the
after-care of BC patients [6, 7]. Breast cancer and its
associated treatments are often linked to a number of
physical and psychosocial changes and uncertainties that
may have a deleterious impact on partnership and sexual-
ity. Though several studies indicate that a majority of BCS
show overall QoL scores comparable to those of the gen-
eral population [8], adverse effects from cancer treatment
can continue to impact upon sexual health (SH) for years
[9–11]. With a prevalence of 23–85%, sexual morbidity is
amongst the most frequent side effects and consequences
of a BC diagnosis and associated treatments [12]. Sexual
morbidity encompasses a wide range of problems and
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symptoms including lack of sexual desire and interest,
body satisfaction, frequency of intercourse, sexual satisfac-
tion, arousal, orgasm, and pain associated with intercourse
[13]. Levels of these sexual problems seem to exceed those
of women with no previous or current BC (WNBC) in the
same age range [6, 8]. Moreover, adverse sexual effects
have been illustrated to be associated with worse cancer-
related distress, depression, symptom severity and overall
QoL [14–16].
Despite an increasing research interest in the relative
contribution of a BC diagnosis to sexual problems in the
long-term, research on the persistence of the well known
disease- and treatment-related sexual adverse effects into
survivorship has received relatively little attention. We cur-
rently lack data on this subject systematically assessed in a
routine clinical setting as data derived from clinical trials
does not usually include this topic. Patients’ subjective per-
spectives, assessed routinely provide complementary infor-
mation contributing to a better understanding of disease-
and treatment-related dysfunction particularly within sensi-
tive domains such as sexuality. Validated patient-reported
outcome (PRO) measures provide an efficient option for a
more comprehensive assessment of SH impairments. More-
over, gathering patient reported information on sexual prob-
lems in BCS can help to improve the detection rates of
sexual adverse effects and therefore make them amenable to
individualized clinical care efforts in daily clinical practice
[17]. This might result in a reduction of sexual problems
and subsequently an improvement of overall QoL in BCS.
Aims
We investigated the self-reported SH outcome of BCS in
routine after-care in comparison to WNBC. Additionally,
predictors of SH were investigated. In detail, we addressed
the following research questions: (1) Does self-reported SH
of BCS differ from those of WNBC? (2) Is the SH of BCS
predicted by treatment-related and clinical variables? (3)
Which self-reported femininity issues, psychosocial issues
and sociodemographic variables predict follow-up SH?
Methods
Sample
Breast cancer survivors
Inclusion criteria for women in the BCS group were the
following: Breast cancer patients who (1) had a con-
firmed diagnosis of BC, (2) were off primary treatment,
(3) had no disease recurrence, (4) were aged 18 years or
older, (5) were fluent in German, and (6) had no overt
cognitive impairment. Clinical data of the BCS group are
presented in Table 1.
Reference sample of women with no previous or
current breast cancer.
For the purpose of comparison, a sample of WNBC
without a history of cancer, who were comparable to the
BCS sample regarding age and education were included
in the study. This reference sample was approached at
the Department of Radiology, Medical University of
Innsbruck. It comprised women attending the routine
screening or any other mammography. Exclusion criteria
were, beside a previous cancer disease, no suspection of
BC as well as the participation at a high risk screening
due to a highly positive family history for BC or a con-
firmed BRCA1 or BRCA 2 mutation.
Procedure
The study was designed as a cross-sectional PRO survey
implemented in routine clinical after-care at the Depart-
ment of Gynecology and Obstetrics, Medical University of
Innsbruck. This includes a consecutive approach of eligible
patients presenting at the Department’s outpatient clinic for
one of their routine after-care check-up. Searching the
clinic’s medical records up-front identified eligible patients.
Patients were approached at their routine after-care check-
up by their treating physician and invited to participate in
the study. The invitation included a short explanation of
the study up-front. If patients were interested, full study in-
formed consent was gathered by the treating physician. Fol-
lowing written informed consent, patients completed a
comprehensive PRO assessment focussed upon SH, body
image, menopausal symptoms and psychological distress.
Menopausal state was assessed dichotomously (pre- vs.
postmenopausal) as reported in the patient’s medical
history. Details on the PRO questionnaires are given below.
Patients were given the opportunity to complete the
assessment semi-anonymously (including only clinical data,
no name).
Table 1 BCS’ clinical characteristics
Breast cancer patients
N = 105%
Time since diagnosis Mean (SD) 3.2 (2.2) years
Range 0.3-17 years
Grading (TNM) Grade I 16.3%
Grade II 60%
Grade III 23.8%
Primary surgical
treatment
Breast conserving
surgery
66.7%
Mastectomy 33.3%
Endocrine treatmenta 64.6%
Current endocrine
treatmentb
53.6%
Radiotherapy 73.5%
Chemotherapy 49.5%
Menopausal state Premenopausal 57.7%
aendocrine treatment received
bOngoing endocrine treatment at assessment time point
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WNBC presenting at Department of Radiology, Medical
University of Innsbruck for their routine or any other
mammography screening for BC were randomly and con-
secutively approached in accordance with the matching
criteria to the BCS sample (age and education). After the
mammography screening confirming the absence of a BC
diagnosis women were approached and invited to join the
study. Consenting participants provided written informed
consent. WNBC completed the same PRO survey as the
BCS sample with some disease-related questions being
adapted. The survey also included sociodemographic in-
formation and information on womens’ medical history
(other chronic disease and current medication intake).
Main outcome measures
Sexual Activity Questionnaire (SAQ).
The SAQ is a reliable and validated short self-report
measure for the assessment of female sexuality in BC pa-
tients [18]. It is composed of 3 sections: items of section
1 contribute to the differentiation of sexual active and
inactive women. In section 2 reasons for sexual inactivity
are assessed. The third section targets on SH only in
sexually active women. Ten items assess pleasure, dis-
comfort with intercourse and habit. The response format
is a 4-point Likert scale with high values indicating high
sexual function.
Sexual interest and desire inventory–female (SIDI-F)
The SIDI-F is a well-validated diagnostic instrument for
the determination of women’s hypo-sexual desire dis-
order (HSDD) [19]. It is composed of 13 items targeting
on the following issues: sexual desire, sexual dysfunction,
sexual behaviour, and sexual relationship. Additional 4
items evaluate some background information on psycho-
logical and physical health issues (partnership satisfac-
tion, negative thoughts, pain, and mood) in order to
better understand the patient’s overall sexual functioning
but do not contribute to the total SIDI-F scoring. Low
scores indicate low sexual functioning. A cut-off of 33 or
lower indicates HSDD. For the purpose of this study, a
self-report version was developed to provide anonymity
particularly for WNBC as well as due to logistic reasons
for the data assessment. Response format and scoring
system corresponded to the original proxy-rating version
(cut-off of ≤33 for HSDD). Psychometric properties of
the self-report version were very satisfactory showing a
high correlation with the SAQ (r = .85, p < .001) and
very good internal consistency (alpha = .925).
Menopause-specific quality of life questionnaire (MENQOL)
The MENQOL was developed as a self-report instru-
ment in order to assess QoL for the menopause [20, 21].
It consists of 29 items composing the subscales vaso-
motor, psychosocial, and sexual symptoms. No overall
sum score is obtained from the questionnaire. Patients
are first asked to indicate the presence of a symptom
and – if present – its severity on a 7-point Likert Scale.
High values indicate high symptoms. The instrument
shows good psychometric properties. The MENQOL has
also been validated for use in breast cancer survivors
(potentially) experiencing menopausal symptoms due to
cancer treatment (endocrine treatment, chemotherapy,
etc.) 22. Menopausal state was recorded in addition.
Body image scale (BIS)
Hopwood and colleagues [22] developed the BIS as a
PRO measure in collaboration with the European Or-
ganisation of Research and Treatment of Cancer Qual-
ity of Life study group for the purpose of assessing
body image in cancer patients. It is a well-validated, 10
items short instrument suitable for use in clinical trials.
The BIS has a single sumscore; the response format is a
4-point Likert scale with high values indicating good
body image.
Hospital anxiety and depression scale (HADS)
The HADS has been developed as a screening instru-
ment for anxiety and depression in somatically ill pa-
tients [23]. It is a 14 items short, self-assessment scale,
with 7 items addressing anxiety and depression each.
Scores of 8 to 10 indicate moderate levels of anxiety or
depression, scores of ≥11 show an anxiety or depressive
disorder. Patients rate their symptom severity on a 4-
point Likert scale. The instrument shows excellent psy-
chometric properties and is widely used in clinical trials
as well as for the purpose of routine screening.
Statistical analysis
Sample characteristics are presented descriptively using
percentages, means, standard deviations, and ranges.
Sociodemographic group comparability of BCS and
WNBC was verified by use of Chi-square test or inde-
pendent t-test (two-sided). Group differences between
BCS and WNBC with regard to the SH status were ana-
lyzed by means of independent t-tests (two-sided). Effect
sizes are indicated by Cohen’s d [24]. We performed a
linear regression analysis for the investigation of predic-
tors of follow-up SH considering menopausal symptoms,
body image, psychological distress, and disease- and
treatment-related variables (backward elimination pro-
cedure). R2 was reported as measure of model determin-
ation; b was employed as a measure of effect size in the
regression analyses, i.e. beta indicates how many units
SH changes per unit increase of the predictor variable.
All analyses were conducted using SPSS 22.
The Ethics Committee of the Medical University of
Innsbruck approved the study (study number UN 5240,
meeting number 329/4.21).
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Results
Patient characteristics
From January to December 2014 patients and WNBC
were included in the study. The final BCS group com-
prised 105 women who were on average 3 years post-
diagnosis (0.3 years to 17 years). A reference sample of
97 WNBC was available for the purpose of comparison.
Please find details for the selection of participants and
inclusion procedure in Fig. 1 and Fig. 2.
In both groups mean age was 49 years (SD = 8.7) and
77% had less or equal to 12 years of education, respect-
ively (matching criteria). No group differences were
found with regard to all sociodemographic characteris-
tics. Please find further details on the sociodemographic
information in Table 2.
SH outcome in BCS compared to WNBC
Twenty-eight percent of BCS and 20% of WNBC
(n.s.) indicated that they were currently sexually in-
active (assessed by means of the SAQ). The primary
reason for sexual inactivity was not having a partner
followed by lack of interest in sex in both groups.
68.8% of BCS and 58.8% of WNBC scored below the
SIDI cut-off of 33 indicating a HSDD.
BCS had significantly more SH impairments than
WNBC according to the SIDI-F (p = 0.005, t = −2.85;
BCS mean = 24.9 vs. WNBC mean = 29.8). In
addition, BCS reported significantly more discomfort
with intercourse (SAQ subscale discomfort) than
WNBC (p = 0.032, t = −2.2; BCS mean = 4.4 vs.
WNBC mean = 5). For both scales, we found moder-
ate effect sizes of 0.4 (according to Cohen), respect-
ively. No differences were found for the SAQ
subscales pleasure (p = 0.21, t = −1.2) and habit
(p = 0.91, t = −0.11). Please find details in Table 3.
Impact of treatment-related and clinical variables on SH
in BCS
For the purpose of better understanding the follow-
up impact of BC disease and treatment on SH out-
come, we considered the following disease- and
treatment-related variables for the correlation and re-
gression analysis: grading, type of surgical treatment,
chemotherapy, radiation, endocrine treatment and
time since diagnosis.
We found no association of these variables with the
SIDI-F sumscore. Grading was the only variable sig-
nificantly associated with SAQ-pleasure (r = −.351,
p = .008) and SAQ-habit (r = −.358, p = .007). In the
linear regression analysis, the predictive value of
lower grading for pleasure and habit was confirmed
explaining 12.3% (pleasure) and 12.8% (habit) of the
variance (Table 4).
The predictive value of self-reported femininity issues,
psychosocial issues and sociodemographic variables on
SH in BCS
We investigated the impact of body image, meno-
pausal symptoms, anxiety and depression, satisfaction
with partnership, menopausal state, age, marital state,
and education as well as time since diagnosis on SH.
The following variables were significantly associated
with follow-up SH outcome (SIDI-F) in an up-front
univariate analysis: depression (HADS p < .001,
r = −.365), menopausal symptoms (MENQOL-psycho-
social p < .001, r = −.380; MENQOL-vasomotor
p = .028, r = −.228; MENQOL-physical p = .001,
r = −.331; MENQOL-sexual p < .001, r = −.568), age
(p = .001, r = −.335), satisfaction with partnership
(SIDI-diagnostic question p < .001, r = .542).
In the multivariate analysis, the predictive value of
higher partnership satisfaction, lower depression and
Fig. 1 BCS selection and inclusion procedure
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lower age on follow-up SH outcome (SIDI-F) was
demonstrated explaining 38.4% of the variance. Please
find details for the respective analysis in Table 5.
Menopausal symptoms had – though significantly cor-
related – no predictive value according to this model
(the MENQOL sexual domain was a priori not in-
cluded in the model since it is supposed to assess the
similar construct as the dependent variable).
Discussion
Cancer survivorship issues have become increasingly
important in post-treatment care during the past dec-
ade. SH and femininity have been identified among the
most crucial subjects for women surviving cancer. In
this study, we aimed to elaborate and understand more
of the relative contribution of a BC diagnosis and its
treatment to female SH over time. For this purpose, the
Fig. 2 WNBC selection and inclusion procedure
Table 2 Sociodemographic characteristics of BCS and WNBC
Breast cancer patients
N = 105%
WNBC
N = 97%
Group difference
Age Mean (SD) 49 years (8.7 years) 49 years (8 years) matched
Range 29-70 years 28-70 years
Age groups <30 2 2
30-40 8.6 8.2
41-50 37 39
51-60 41 42
>60 11.4 8.2
Marital status Single 17.3% 7.2% p = 0.057
Partnership, marriage 76% 88.7%
Divorced, separated 6.7% 4.1%
Education Compulsory school or less 9.6% 7.2% matched
Apprenticeship/ professional school 49% 48.5%
A-level 19.2% 20.6%
University degree 21.2% 22.7%
Other 1% 1%
Employment Full time 24.3% 34% p = 0.097
Part time 35.9% 43.3%
Unemployed 3.9% 1%
Homemaker 7.8% 8.2%
Retired 21.4% 9.1%
Other 6.8% 4.1%
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consideration of subjective patient data is inevitable.
We investigated self-reported levels and predictors of
SH outcome in BCS in the clinical routine in compari-
son to WNBC.
Even years after treatment, BC patients still reported
distinct levels of sexual health impairments that differed
significantly from that of women without a history of
BC. BCS were not only more frequently sexually in-
active, but also met the criteria for a HSDD more often.
Almost 70% of BCS qualified for a HSDD based on self-
reports which is comparable to results from a recent
study from Raggio and colleagues [25] who found rates
of even 77% in BCS using the FSFI as outcome measure.
Similar findings were reported by Panjari and colleagues
[10] who observed sexual functioning problems in 70%
of BC patients up to 12 months post-diagnosis.
Overall, BCS reported worse SH than WNBC (accord-
ing to the SIDI-F). This result complements previous find-
ings of higher sexual dysfunction observed in BC patients
short after treatment [17, 26–28]. Our results confirm
some previous evidence. Already15 years ago, Dorval and
colleagues [29] reported that BCS did not differ from
population controls in all QoL domains except sexuality,
which was worse in BC patients. However, despite the in-
vention of new treatment regimes and treatment efforts
SH impairments still seem to be a major problem related
to BC. Only recently, Boquiren and colleagues [30]
illustrated that BCS experienced poorer sexual functioning
than the female general population. Corresponding results
have been obtained by Bredart and colleagues [31]. Par-
ticularly, the issue of discomfort with intercourse seems to
be a major factor contributing to this difference. Quite
surprisingly, pleasure and habit was not significantly dif-
ferent based on results derived from the SAQ in this
study. However, this finding can partly be explained by the
questionnaire construction. Patients who are sexually in-
active do not complete the questions on pleasure and
habit so that inactive patients are not included for the ana-
lysis of these scales. Considering sexual inactivity as highly
sexually dysfunctioning, we can assume that these results
tend to underscore the real level of dysfunction in the
BCS group. In view of the SIDI-F pleasure items, herein
completed also by inactive women, we found impairments
also for pleasure and habit.
The previously reported higher deteriorating effect of
chemotherapy and mastectomy [32–35] on SH com-
pared to breast conserving surgery and other adjuvant
treatments in or short after the treatment phase seems
to be no longer prevalent in the follow-up period. We
did not observe an association of any treatment-related
variables with SH in BCS. Though corresponding results
were observed previously [31], this is in contrast to other
established findings. For instance, Raggio and colleagues
[25] found mastectomy to have late effects on SH in a
Table 3 Differences between BCS and WNBC regarding their SH outcome, presentation of (sub)scale results
BCS Mean (SDe) WNBC Mean (SDe) T-Test Difference ESc, pd
SIDI-Fa 24.9 (13) 29.8 (10.74) −2.85 4.9 0.41, 0.005
SAQb – discomfort with intercourse 4.4 (1.9) 5 (1.4) −2.2 0.6 0.36, 0.032
SAQb - habit 1.8 (0.9) 1.8 (0.9) −0.11 0 0, 0.9
SAQb - pleasure 9.5 (4.8) 10.4 (4.6) −1.26 0.9 0.19, 0.2
aSIDI-F
bSexual Activity Questionnaire
cCohen’s effect size
da p value below 0.05 was considered significant
eStandard deviation
Table 4 Linear regression model on the association of treatment-related and clinical variables on SH in BCS (n = 105)
Predictors SAQ- pleasure R2 c = 12.3% SAQ- habit R2 = 12.8%
βa t pb 95% CL Lower-upper bound β t pb 95% CL Lower-upper bound
Gradingd −2.65 −2.756 0.008 −4.6–0.7 −.53 −2.818 0.007 −0.9-0.15
Type of surgical treatment 0.130 1.009 .318 .012 .090 .929
Chemotherapy −.006 −.041 .967 −.026 −.192 .849
Radiation −.039 −.301 .765 −.112 −.865 .391
Endocrine treatment −.102 −.744 .460 .135 .992 .326
abeta coefficient
ba p value below 0.05 was considered significant
cR2: explained variance by the model
ddichotomized variable (grade 1 vs. higher grades)
italic print indicates significance
CL: 95% confidence interval
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smaller sample of BCS up to 7 years post-treatment. Evi-
dence, hence, is somehow inconsistent and needs further
elaboration. Larger patient samples would allow the
comparison of different chemotherapeutic agents and/or
combination treatments regarding their influence on SH
which might give further insight into this subject. How-
ever, the extent of disease proliferation – indicated by
the grade of disease herein – seems to play a role for
follow-up SH outcome.
Depressive symptoms, age, and partnership satisfaction
seem to be crucial factors for follow-up SH outcome.
Low partnership satisfaction and quality are well known
to be among the strong factors deteriorating BCS’ SH
[31, 36, 37]. This is true also for SH in women without a
history of BC [38, 39]. Higher psychological distress and
higher age have previously been observed to be associ-
ated with reduced SH [26, 40, 41]. Our study findings,
thus, confirm established evidence. The role of body
image regarding SH outcome seems to be somewhat
contradictory. We could not find body image to –
though associated – be central to SH problems BCS de-
velop; so did others [42]. However, on the contrary, sub-
stantial evidence suggests body image to be among the
most important issues for SH after BC [3, 10, 31]. This
heterogeneity might be explained by different study
groups, study designs, and sample sizes. There are hardly
any studies that evaluated the association of body image
and sexuality by use of a longitudinal study design with
a homogeneously defined baseline and covering a sub-
stantial follow-up period. The latter design might con-
tribute to a more precise picture of this association.
Another interesting finding of this study is the re-
ported rate of 60% of HSDD in WNBC. This observation
underscores previous estimates of sexual dysfunction as
a crucial female problem in general, ranging from 25%
to 63% [43]. A BC diagnosis and treatment seems to ag-
gravate this problem of a pretty high pre-diagnosis im-
pairment “level”.
At this point some study limitations have to be dis-
cussed. Firstly, we designed the study cross-sectionally.
A longitudinal study design including baseline data
might have given additional insight into changes of SH
over time. Secondly, the use of the SIDI-F as a self-
report version has not been validated previously. How-
ever, scale reliability and correlation with the widely used
and validated PRO measure SAQ was excellent. Subse-
quently, we can assume this measure to provide validate
results. The anonymous completion of questions offered
to the patient was considered to contribute to the reduc-
tion of potential response bias immanent to PRO assess-
ments. In addition, the potential for selection bias is
immanent to studies with a consecutive, unsystematic
inclusion procedure. Thirdly, the definition for survivor-
ship used in this study ecompasses the includion of a
broad range of patients at different stages post treatment
(0.3–17 years), so that the patient comparability might
Table 5 Linear regression model on the association of self-reported femininity issues, psychosocial issues and sociodemographic
variables on SH in BCS (n = 105)
Predictors SIDI-F R2 e = 38.4%
β t Pf 95% CL
BISa −0.064 −0.67 0.505
MENQOLb
Vasomotor −004 −0.431 0.668
Psychosocial −0.13 −1.028 0.307
Physical −0.144 −1.378 0.652
HADS-depressionc −.94 2.7 0.008 −1.646-0.238
HADS-anxietyc 0.108 0.948 0.346
Satisfaction with partnershipd 3.664 5.2 <0.001 2.27-5.05
Menopausal state (pre- vs. post menpausal)g −0.069 −0.496 0.621
Ageg −.307 −2.1 0.039 −0.585-0.028
Marital state (with vs. without partnership)g −0.17 −1.154 0.124
Education (less vs. more than compulsory school)g 0.072 0.799 0.427
Time since diagnosis 0.012 0.137 0.892
aBody image scale
bMenopause-Specific Quality of Life Questionnaire
cHospital anxiety and Depression Scale
dderived from the SIDI-diagnostic question on partnership satisfaction
eR2: explained variance by the model
fp value below 0.05 was considered significant
gdichotomous variables
CL: 95% confidence interval
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be questioned in this regard. However, we controlled for
this factor including time since diagnosis in the analysis
showing no impact of this variable on patients’ SH. In
addition, this is an issue immanent to survivorship stud-
ies in general.
Conclusion
Our results demonstrate that SH problems persist into BC
survivorship and differ significantly from the general popu-
lation. Sexuality should be regarded as major health care
demand in BC survivorship care, as supported also by other
authors [44]. A sensibilisation of health care providers to-
wards this subject can be the first step in the improvement
of care efforts. Health care providers can break the taboo
by addressing SH with the patient as an important survivor-
ship issue in their routine survivorship care/ counselling.
The integration of PRO into routine survivorship health
care can provide in addition an efficient option to improve
the detection of SH problems. Moreover, the routine use of
PRO has been observed to facilitate patient-clinician com-
munication and consequently contributes to patient em-
powerment and patient satisfaction. Awareness and an
improved detection of a SH problem can help patients to
express their care demands and contribute to targeting
treatment efforts. Depending on their SH care demands,
patients might be offered some educational information or
be referred to a psychologist or gynaecologist specialized
on SH for in-depth treatment. Multi-modal treatment op-
tions offered by a multi-professional team seem to be most
promising for the management of SH problems [44]. How-
ever, further reaearch on targeted interventions is required
as there are currently hardly any state-of-the-art treatment
recommendations for SH for BCS available. Consequently,
the treatment of depressive symptoms and partnership
problems can contribute to increase not only overall QoL
but also BCS’ SH. This is of vital importance with reagard
to the sensitive QoL aspect of SH.
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